Sciclone Pharma (SCLN) Reports Better-Than-Expected Q4 Results; Guides FY12
Tweet
Share
E-mailGet Alerts SCLN Hot Sheet
Price: $11.15 --0%
Financial Fact:
Provision for income tax: 1.06M
Today's EPS Names:
VAXX, EGRX, AFIB, More
Financial Fact:
Provision for income tax: 1.06M
Today's EPS Names:
VAXX, EGRX, AFIB, More
Join SI Premium – FREE
Sciclone Pharmaceuticals, Inc. (NASDAQ: SCLN) reported Q4 EPS of $0.20, $0.08 better than the analyst estimate of $0.12. Revenue for the quarter came in at $41.4 million versus the consensus estimate of $40.39 million.
Sees FY2012 EPS of $0.72-$0.78, versus the consensus of $0.43. Sees FY2012 revenue of $165-$170 million, versus the consensus of $168 million.
For earnings history and earnings-related data on Sciclone Pharmaceuticals, Inc. (SCLN) click here.
Sees FY2012 EPS of $0.72-$0.78, versus the consensus of $0.43. Sees FY2012 revenue of $165-$170 million, versus the consensus of $168 million.
For earnings history and earnings-related data on Sciclone Pharmaceuticals, Inc. (SCLN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Wolfe Research downgrades Stryker, upgrades Abbott in med-tech shuffle
- Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
